• Journal of Chest Surgery
• /
• 제33권5호
• /
• pp.385-390
• /
• 2000

Background: To review the experience that used both ventricular assist device(VAD) and extracorporeal membrane oxygenation(ECMO) for children with congential heart disease requiring postcardiotomy mechanical circulatory support. Material and Method: Between March 1993 and May 1995, we applied mechanical assist device using centrifugal pump to the 16 patients who failed to be weaned from cardiopulmonary bypass(n=15) or had been in cardiogenic shock in intensive care unit(n=1). The diagnosis were all congenital heart diseases and the ages of patients ranged from 20 days to 10 years (mean age=2.5$\pm$3.5 years). Result: The methods of mechanical circulatory support were LVAD(n=13), BVAD (n=1), and ECMO(n=2). The mean assist times were 54.0$\pm$23.7 hours. Post-assist complications were in orders: bleeding, acute renal failure, ventricular failure, respiratory failure, infection, and neurologic complication. It was possible for 9 patients(56.3%) to be weaned from assist device and 5 patients(31.3%) were discharged from hospital. There was no statistical significant between hospital discharged group and undischarged group by age, body weight, cardiopulmonary bypass time, and assist time. Conclusion: The ventricular assist device is an effective modality in salvaging the patient who failed to be weaned from cardiopulmonary bypass, but multiple factors must be considered for improving the results of mechanical circulatory support ; such as patient selection, optimal time of starting the assist device, and prevention and management of the complications.

• Journal of Chest Surgery
• /
• 제52권2호
• /
• pp.105-108
• /
• 2019

Right heart failure is a relatively common complication after left ventricular assist device (LVAD) implantation. Severe right heart failure can be managed by temporary right ventricular assist device (RVAD) implantation. However, trans-sternal RVAD insertion requires a subsequent third sternotomy for cannula removal. Herein, we present a case of RVAD insertion via a left anterior mini-thoracotomy after LVAD implantation in a patient with alcohol-induced cardiomyopathy.

• Journal of Chest Surgery
• /
• 제53권2호
• /
• pp.79-81
• /
• 2020

Treatment options for children with end-stage heart failure are limited. We report the first case of a successful pediatric heart transplantation bridged with a durable left ventricular assist device in Korea. A 10-month-old female infant with dilated cardiomyopathy and left ventricular non-compaction was listed for heart transplantation. During the waiting period, the patient's status deteriorated. Therefore, we decided to provide support with a durable left ventricular assist device as a bridge to transplantation. The patient was successfully bridged to heart transplantation with effective support and without any major adverse events.

• 한국기계가공학회지
• /
• 제12권4호
• /
• pp.22-28
• /
• 2013

It is important to begin left ventricular assist device (LVAD) treatment at appropriate time for heart failure patients who expect cardiac recovery after the therapy. In order to predict the optimal timing of LVAD implantation, we predicted pumping efficacy of LVAD according to the severity of heart failure theoretically. We used LVAD-implanted cardiovascular system model which consist of 8 Windkessel compartments for the simulation study. The time-varying compliance theory was used to simulate ventricular pumping function in the model. The ventricular systolic dysfunction was implemented by increasing the end-systolic ventricular compliance. Using the mathematical model, we predicted cardiac responses such as left ventricular peak pressure, cardiac output, ejection fraction, and stroke work according to the severity of ventricular systolic dysfunction under the treatments of continuous and pulsatile LVAD. Left ventricular peak pressure, which indicates the ventricular loading condition, decreased maximally at the 1st level heart-failure under pulsatile LVAD therapy and 2nd level heart-failure under continuous LVAD therapy. We conclude that optimal timing for pulsatile LVAD treatment is 1st level heart-failure and for continuous LVAD treatment is 2nd level heart-failure when considering LVAD treatment as "bridge to recovery".

• Journal of Chest Surgery
• /
• 제48권6호
• /
• pp.407-410
• /
• 2015

A two-month-old infant presented with coarctation of the aorta, severe left ventricular dysfunction, and moderate to severe mitral regurgitation. Through median sternotomy, the aortic arch was repaired under cardiopulmonary bypass and regional cerebral perfusion. The patient was postoperatively supported with a left ventricular assist device for five days. Left ventricular function gradually improved, eventually recovering with the concomitant regression of mitral regurgitation. Prompt surgical repair of coarctation of the aorta is indicated for patients with severe left ventricular dysfunction. A central approach for surgical repair with a back-up left ventricular assist device is a safe and effective treatment strategy for these patients.

• 대한의용생체공학회:의공학회지
• /
• 제23권1호
• /
• pp.33-38
• /
• 2002

심실보조장치(ventricular assist device, VAD)는 그 특성상 손상된 자연심장의 기능을 보조하기 위해서 사용된다. 따라서, 심실보조장치의 제어 알고리즘을 고려할 때에는 가능한 한 자연심장에 걸리는 부하를 최소한으로 줄여주는 것이 중요하다. 이처럼 자연심장에 걸리는 부하를 줄여주기 위해 가장 일반적으로 사용되는 제어 방식이 바로 자연심장과 심실보조장치 상호간의 동시 박출을 방지하는 counterpulsation 제어 방식이다. 실제로 Nanas[1][2] 등은 동물실험을 통해 좌심실이 손상된 상황에서 counterpulsation 장cl가 혈류역학적으로 어떠한 영향을 미치는가를 연구하였다 본 연구에서는, 현재 서울대학교 인공심장연구실과 (주)바이오메드랩에서 공동으로 개발 중인 이동작동기형 심실보조장치 (AnyHeart/ sup TM/)에 사용할 수 있는 counterpulsation 제어 알고리즘을 개발하고. 개발된 알고리즘을 실제 동물 실험에 적용하기에 앞서 모의순환장치를 이용하여 개발된 알고리즘의 효용성을 검증하여 보았다. 자연심장의 박출 상태를 실시간으로 파악하기 위해 심전도(electrocardiogram, ECG) 신호를 입력으로 받아들여 제어를 수행하는 방식을 채택하였으며, 모의순환장치에서의 실험 결과 심실보조장치와 자연심장 간의 동시 박출 방지 효과가 정상적으로 일어남을 확인할 수 있었다.

• Journal of Chest Surgery
• /
• 제27권12호
• /
• pp.977-983
• /
• 1994

From April 1989 to December 1993, total 39 patients who were unable to be weaned off CPB or expected fatal immediate postoperiatively, were treated with ventricular assist device [VAD] or extracorporeal membrane oxygenator[ECMO] at the Royal Children`s Hospital, Melbourne. Ages ranged from 3 day to 19.4 year old and body weights from 2.0Kg to 70Kg. Twenty-seven[69.2%] of 39 patients were weaned to be decannulated successfully and sixteen[41.0%] survived to hospital discharge and late survival rate was twelve[30.8%] of 39 patients. The total follow-up period was 4 to 56 months [32.92$\pm$20.77months] and most of the late survivals showed good myocardial recovery state. From the viewpoint of the assist modality, 29 patients were treated with VAD and among them, 23 were weaned from assist successfully, but among the 8 ECMO patients, only 3 could be weaned, and both modalities were performed to the 2 patients with one weaned. The total duration of assist was from 8 to 428 hours and there was a significant difference between hospital discharged group and hospital death group, which were 83.13$\pm$31.29 hours vs 147.52$\pm$112.03 hours[P=0.032]. Conclusively, at the critical postcardiotomy situation of the paediatrtic patients including various congenital complex disease and procedures, we can choose this VAD or ECMO treatment strategy as the reasonable life saving way except transplantation.

• Journal of Chest Surgery
• /
• 제57권3호
• /
• pp.312-314
• /
• 2024

A 3-year-old boy with Glenn physiology exhibited refractory heart failure with reduced ejection fraction. To improve the patient's oxygen saturation, he underwent ventricular assist device (VAD) implantation with concomitant Fontan completion. The extracardiac conduit Fontan operation was performed with a 4-mm fenestration. For VAD implantation, Berlin Heart cannulas were positioned at the left ventricular apex and the neo-aorta. Following weaning from cardiopulmonary bypass, a temporary continuous-flow VAD, equipped with an oxygenator, was utilized for support. After a stabilization period of 1 week, the continuous-flow VAD was replaced with a durable pulsatile-flow device. Following 3 months of support, the patient underwent transplantation without complications. The completion of the Fontan procedure at the time of VAD implantation, along with the use of a temporary continuous-flow device with an oxygenator, may aid in stabilizing postoperative hemodynamics. This approach could contribute to a safe transition to a durable pulsatile VAD in patients with Glenn physiology.

• Journal of Chest Surgery
• /
• 제57권2호
• /
• pp.184-194
• /
• 2024

Background: Left ventricular assist devices (LVADs) are widely employed as a therapeutic option for end-stage heart failure. We evaluated the outcomes associated with centrifugal-flow LVAD implantation, comparing 2 device models: the Heartmate 3 (HM3) and the Heartware Ventricular Assist Device (HVAD). Methods: Data were collected from patients who underwent LVAD implantation between June 1, 2015 and December 31, 2022. We analyzed overall survival, first rehospitalization, and early, late, and LVAD-related complications. Results: In total, 74 patients underwent LVAD implantation, with 42 receiving the HM3 and 32 the HVAD. A mild Interagency Registry for Mechanically Assisted Circulatory Support score was more common among HM3 than HVAD recipients (p=0.006), and patients receiving the HM3 exhibited lower rates of preoperative ventilator use (p=0.010) and extracorporeal membrane oxygenation (p=0.039). The overall early mortality rate was 5.4% (4 of 74 patients), with no significant difference between groups. Regarding early right ventricular (RV) failure, HM3 implantation was associated with a lower rate (13 of 42 [31.0%]) than HVAD implantation (18 of 32 [56.2%], p=0.051). The median rehospitalization-free period was longer for HM3 recipients (16.9 months) than HVAD recipients (5.3 months, p=0.013). Furthermore, HM3 recipients displayed a lower incidence of late hemorrhagic stroke (p=0.016). In the multivariable analysis, preoperative use of continuous renal replacement therapy (odds ratio, 22.31; p=0.002) was the only significant predictor of postoperative RV failure. Conclusion: The LVAD models (HM3 and HVAD) demonstrated comparable overall survival rates. However, the HM3 was associated with a lower risk of late hemorrhagic stroke.

• Journal of Chest Surgery
• /
• 제30권3호
• /
• pp.247-252
• /
• 1997

심장이식시에 가교 역할을 담당하거나 수술 후 심부전에 빠진 심장을 보조할 공압식 심실보조장치를 개발하여 동물실험을 시행하였다. 실험 에 이용한 심실보조장치는 소아용과 성 인용의 두 가지 종류로서 박동장이 각각 34cc와 70cc이다. 심실 재료는 폴리우레탄으로 제작하여 항혈전성을 높였다. 총 10마리의 동물실험을 시행하였다. 심실보조장치의 혈액펌프는 좌심방과 대동맥에 연결관을 이용하여 이식하였다. 심실보조장치의 평균 박출량은 펌프 박동수가 60회일 때 성 인의 경우 2.38 L/min였고 소아용의 경우 0.41 L/min였다. 생존시간은 최고 26시간이었다. 가장 큰 합병증은 출혈이었고 주 사망원인은 심부전 및 폐부전이었다. 심실보조장치 자체 에 대한 결함때문에 일어난 실패는 없었다. 현재까지의 실험 결과를 토대로 심실보조장치를 발전시키면 임상에서도 사용 가능할 것으로 보인다.